top of page

Insights and News Curated for Life Science Experts by Life Science Experts....
INSIGHTS HUB


Warren Buffett’s Hiring Rule: Why Integrity Comes First
Warren Buffett’s hiring philosophy has long been quoted in business circles, and for good reason. As he prepares to step down as CEO of...


Deepfakes: A Growing Threat to Hiring in the Life Sciences Industry
As Life Sciences recruiting becomes more selective and AI has continued advancement, incorporating these technologies into recruitment...


The FTC Ban on Non-Competes – From Life Science Recruiters’ Perspective
In a landmark decision, the Federal Trade Commission (FTC) has voted 3-2 to approve the issuance of a final rule that could reshape the...
Search
Danaher Corporation to Acquire Masimo Corporation for $9.9B
Washington, February 17, 2026 (PRNewswire) -- Danaher Corporation announced it has signed a definitive agreement to acquire Masimo Corporation, a leader in pulse oximetry and advanced patient monitoring technologies, in an all-cash deal valued at approximately $9.9 billion, including assumed debt. Under the agreement, Danaher will pay $180 per share in cash, representing a transaction multiple of roughly 18x estimated 2027 EBITDA, or 15x including expected synergies. Masimo
BD closes $18.8B Biosciences & Diagnostic Solutions deal with Waters
Franklin Lakes, NJ, February 9, 2026 (PRNewswire) -- BD said it has completed the spin-off of its Biosciences & Diagnostic Solutions business and combined it with Waters Corporation, finalizing the previously announced transaction. At closing, BD shareholders received Waters shares representing 39.2% of the combined company (fully diluted), and BD said the business was valued at $18.8B based on Waters’ Feb. 6, 2026 closing price. BD also said it plans to deploy $2B toward a
Helus Pharma taps longtime CNS pharma leader Michael Cola as CEO
Boston and Toronto, February 10, 2026 (Globe Newswire) -- Helus Pharma named Michael Cola Chief Executive Officer, effective immediately, as the company shifts into a “scale and execution” phase. Cola previously led Shire’s Specialty Pharmaceutical business and brings 30+ years across neuroscience, rare disease, and specialty pharma, with experience spanning late-stage development and global commercialization. The company said the timing aligns with upcoming milestones, inc
Eikon prices upsized IPO at $18 to raise about $381M
Millbrae, CA, February 4, 2026 (Globe Newswire) -- Eikon Therapeutics set the price for an upsized initial public offering of 21,177,600 common shares at $18.00 each and granted underwriters a 30-day option to buy up to 3,176,640 additional shares. The company expects gross proceeds of roughly $381 million before fees and expenses (excluding any proceeds from the option), with trading anticipated to begin on Feb. 5, 2026, subject to customary closing conditions. Read full a
ZOLL names Eric Knudsen CEO in April Leadership Transition
Chelmsford, M A, February 4, 2026 (ZOLL) -- ZOLL Medical (an Asahi Kasei company) appointed Eric Knudsen as Chief Executive Officer, effective April 1, 2026. Knudsen will succeed Jon Rennert, who led ZOLL for the past 10 years and will move into the role of Executive Chairman of the Board. ZOLL highlighted Knudsen’s nearly 30 years in medtech, including leading corporate development at ZOLL and most recently serving as President of ZOLL Itamar, where he oversaw significant
Lilly to buy Orna Therapeutics for up to $2.4B to push in vivo CAR-T Cell Therapies
Indianapolis and Watertown, MA, February 9, 2026 (PRNewswire) -- Eli Lilly signed a definitive agreement to acquire Orna Therapeutics, adding a circular RNA + lipid nanoparticle platform designed to engineer immune cells inside the body rather than via traditional ex vivo manufacturing. Read full article here .
Mendra launches with $82M Series A to build AI-driven Rare Disease Therapeutics Platform
San Francisco, CA, January 22, 2026 (Business Wire) -- Mendra launched with an oversubscribed $82 million Series A financing to acquire, develop, and commercialize therapies for rare diseases with high unmet need. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The company plans to leverage artificial intelligence to accelerate patient identification, clinical trial enrollment, and global commercialization as it build
Millrock Technology Names Industry Veteran Tom Hochuli as CEO
Kingston, NY, January 27, 2026 (PRNewswire) -- Millrock Technology has appointed Tom Hochuli as Chief Executive Officer, bringing more than 30 years of leadership across life sciences, medical devices, and biologics manufacturing. Hochuli joins at a pivotal growth stage and is expected to strengthen Millrock’s position as a trusted innovator in advanced freeze-drying and processing technologies for pharma and biotech customers. His background includes leading operational tr
Anteris Secures Medtronic Backing in $320M Capital Raise to Push TAVR Program Forward
Minneapolis & Brisbane, January 22, 2026 (Globe Newswire) -- Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic, bringing total gross proceeds to $320 million when combined with a concurrent underwritten equity offering. The funding will support execution of Anteris’ global pivotal PARADIGM trial and accelerate progress toward worldwide commercialization of its DurAVR® transcatheter heart valve for aortic stenosis. Company leaders
Peter Melnyk Takes the Helm as President and CEO of Taiho Oncology
Princeton, NJ, January 28, 2026 (Business Wire) -- Taiho Oncology appointed Peter Melnyk as President and Chief Executive Officer, effective immediately, following the retirement of Tim Whitten after 13 years of leadership. Melnyk brings more than three decades of experience in oncology commercialization across pharma, biotech, and medical devices, most recently serving as Chief Commercial Officer at Alpha Tau Medical. His appointment comes as Taiho Oncology builds on recen
CORXEL raises up to $287M to Advance Oral GLP-1 and Cardiometabolic Pipeline
Berkeley Heights, NJ, January 22, 2026 (Globe Newswire) -- Corxel Pharmaceuticals closed a Series D1 financing of up to $287 million to accelerate development of its cardiometabolic portfolio, led by the oral small-molecule GLP-1 receptor agonist CX11. The proceeds will fund ongoing U.S. Phase 2 studies in obesity and overweight patients, planned global Phase 2 trials in type 2 diabetes, early Phase 3 preparations, and additional programs spanning acute ischemic stroke and
Inquis Medical Raises $75M Series C to Expand AVENTUS Thrombectomy Adoption
Menlo Park, CA, January 12, 2026 (Business Wire) -- Inquis Medical closed a $75 million Series C financing from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation pipeline. The raise follows a pivotal year in which the company transitioned to a commercial-stage organization, expanded regulatory clearance for pulmonary embolism, and published positive pivotal trial data demonstrat
bottom of page

